Page History

...

The second project was intended to address the unmet need for integrating quantitative imaging biomarkers into current risk stratification tools and to explore the correlation between radiomics features –alone or in combination with clinical prognosticators- and tumor outcome.  Clinical meta-data and matched baseline contrast-enhanced computed tomography (CECT) scans were used to build a cohort of 495 oropharyngeal cancer (OPC) patients treated between 2005 and 2012.  Expert radiation oncologists manually segmented primary and nodal disease gross volumes (GTVp & GTVn). Structures were named per the American Association of Physicists in Medicine (AAPM) TG-263 recommendations, then retrieved in RT-STRUCT format. Matched patient, disease, treatment and outcomes data were obtained. Radiomics analysis was performed using an open-source institutionally-developed software that runs on Matlab platform.  More information about this study and links to download the corresponding patient subset of this collection including clinical data can be found at Radiomics outcome prediction in Oropharyngeal cancer.

Acknowledgements:

This research was supported by the Andrew Sabin Family Foundation; Dr. Fuller is a Sabin Family Foundation Fellow. Drs. Mohamed and Fuller receive funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (NIDCR) (R01DE025248) and the National Institutes of Health (NIH)/National Cancer Institute (NCI) (1R01CA214825-01). Dr. Fuller received/(s) grant and/or salary support from the NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Career Development Award (P50CA097007-10); the NCI Paul Calabresi Clinical Oncology Program Award (K12 CA088084-06); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award;  an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center Seed Grant; the MD Anderson Institutional Research Grant (IRG) Program; and the NIH/NCI Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center (P30 CA016672). Dr. Elhalawani was directly funded in part by a philanthropic gift from the Family of Paul W. Beach given to Dr. Gunn for patient-outcome database construction.

...